Cervical cancer screening is an essential tool for reduction of associated incidence and mortality. Currently, high-risk Human Papilloma Virus (hr-HPV) testing is the first line of cervical cancer screening. This method is highly sensitive but with limited specificity. Thus, the research teams from IPOPorto and Administração Regional de Saúde do Norte tested DNA methylation-based biomarkers in formalin-fixed paraffin embedding samples and cervical smears for triage of women positive for hr-HPV.
